NEUROCRINE BIOSCIENCES INC
Other · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B |
| Operating income | $619.1M | $570.5M | $250.9M | $249.0M | $102.5M | $163.0M |
| Net income | $478.6M | $341.3M | $249.7M | $154.5M | $89.6M | $407.3M |
| Total assets | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B | $1.73B |
| Total liabilities | $1.38B | $1.13B | $1.02B | $660.9M | $698.5M | $608.5M |
| Equity | $3.25B | $2.59B | $2.23B | $1.71B | $1.37B | $1.13B |
| EPS (diluted) | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 |
| Shares out. | 99.7M | 99.5M | 96.6M | 95.2M | 93.9M | 92.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 21.6%
- Net margin
- 16.7%
- Return on equity
- 14.7%
- Return on assets
- 10.3%
- Return on capital (ROCE)
- 15.9%
- Liabilities / assets
- 29.8%
- Debt / equity
- 0.42×
- Book value / share
- $32.63
- Revenue growth (YoY)
- 21.4%
- Net income growth (YoY)
- 40.2%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 6.21safe
- Accruals / assets
- −6.6%clean
- Beneish M-Score
- -2.47normal
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 6 good- Operating margin is positive
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Capital Management LlcPassive (13G)Apr 30, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Jpmorgan Chase & CoPassive (13G)Jan 21, 2026
- Dodge & CoxPassive (13G)May 14, 2025
- Blackrock, Inc.Passive (13G)Apr 28, 2025
- State Street CorpPassive (13G)Feb 5, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Material events
SEC Form 8-K · most recent- Director / officer change · Shareholder voteMay 28, 2026
- Entered a material agreement · Completed an acquisition or disposition · New financial obligation · Regulation FD disclosureMay 18, 2026
- Results of operationsMay 5, 2026
- Entered a material agreementApr 6, 2026
- Results of operationsFeb 11, 2026
- Director / officer changeNov 24, 2025
- Results of operationsOct 28, 2025
- Results of operationsJul 30, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.